<DOC>
	<DOCNO>NCT00441441</DOCNO>
	<brief_summary>This study ass safety investigational drug child 4 11 year age asthma . The subject attend 7 clinic visit , 3 morning , lung function test perform .</brief_summary>
	<brief_title>A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane ( HFA ) Versus Fluticasone Propionate 100 HFA In Children With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Must asthma . Must currently take inhale corticosteroid . Must able attend 7 clinic visit , 3 morning , lung function test least 60 % normal ( AM FEV1 PEF ) . Have historical current FEV1 PEF reversibility &gt; =12 % . Exclusion criterion : Has ever lifethreatening asthma ( example respiratory arrest , mechanical ventilation ) . Has current ear respiratory tract infection . Has ever major illness ( cystic fibrosis , heart problem , tuberculosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>fluticasone propionate</keyword>
	<keyword>child</keyword>
	<keyword>fluticasone propionate/salmeterol</keyword>
</DOC>